An OMV Vaccine Derived from a Capsular Group B Meningococcus with Constitutive FetA Expression: Preclinical Evaluation of Immunogenicity and Toxicity

dc.contributor.author	Norheim, Gunnstein
dc.contributor.author	Sanders, Holly
dc.contributor.author	Mellesdal, Jardar Wollan
dc.contributor.author	Sundfør, Idunn
dc.date.accessioned	2015-10-21T13:31:43Z
dc.date.accessioned	2015-11-09T13:49:36Z
dc.date.available	2015-10-21T13:31:43Z
dc.date.available	2015-11-09T13:49:36Z
dc.date.issued	2015
dc.identifier.citation	PLoS ONE 2015, 10(9)
dc.identifier.issn	1932-6203
dc.identifier.uri	http://hdl.handle.net/11250/2359760
dc.description	-
dc.language.iso	eng
dc.relation.uri	http://www.plosone.org/article/fetchObject.action?uri=info:doi/10.1371/journal.pone.0134353&representation=PDF
dc.title	An OMV Vaccine Derived from a Capsular Group B Meningococcus with Constitutive FetA Expression: Preclinical Evaluation of Immunogenicity and Toxicity
dc.type	Journal article
dc.date.updated	2015-10-21T13:31:43Z
dc.identifier.doi	10.1371/journal.pone.0134353
dc.identifier.cristin	1282437